期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 138, 期 2, 页码 367-+出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2016.03.025
关键词
Allergic rhinitis; conjunctivitis; Allergic Rhinitis and its Impact on Asthma; MACVIA-LR; information and communication technology; clinical decision support system
资金
- Actelion
- Almirall
- Meda
- Merck
- Merck Sharp Dohme
- Novartis
- Sanofi Aventis
- Takeda
- Teva
- Uriach
- AstraZeneca
- Chiesi
- GlaxoSmithKline
- OM Pharma
- Sanofi-Aventis
- Schering- Plough
- Research in Real Life
- Mundipharma
- ALK-Abello
- Allergopharma
- Allergy Therapeutics
- Anallergo
- Hal
- Lofarma
- Stallergenes
- Thermo Fisher
- Genentech
- Circassia and Biomay
- Boehringer Ingelheim
- Cipla
- Sanofi Pasteur MSD
- Boehringer Ingelheim International
- Stallergenes France
- Air Liquide Sante International
- Circassia
- ThermoFisher Scientific
- DBV
- Menarini
- MSD
- Napp
- Fundacao Ciencia e Tecnologia and Fundacao Calouste Gulbenkian
- Aerocrine
- Vitoria
- European Union project MeDALL
- European Union project iFAAM
- Adamed
- Pfizer
- Polpharma
- Lekam
- Bayer
- Celon Pharma
- FAES
- Sanofi
- UCB
- Senosiain
- Carnot
- Glenmark
- EU MedALL
- National and regional public funding applications
- Church Dwight
- Greer
- Johnson Johnson
- Mylan
- Regeneron/Sanofi
- Hartington Pharmaceuticals
- Pierre-Fabre
- Nestle
- Abbvie
- Amgen
- UK National Health Service
- British Lung Foundation
- AKL Ltd
- Respiratory Effectiveness Group
- Zentiva
- Kyorin
- SkyePharma
- Orion
- European Union Social Fund
- Lithuanian Ministry of Health
- European Academy of Pediatrics
- Microtest Dx
- Ansell
- Bayer Schering
- Fujisawa
- Henkel
- Kryolan
- Leti
- Procter Gamble
- Ranbaxy
- Schering Plough
- Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish
The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据